Literature DB >> 19538521

HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.

C S P Tsang1, I Hong.   

Abstract

Highly active antiretroviral therapy (HAART), using HIV protease inhibitors, is commonly used in the management of HIV infection. HIV protease inhibitors also have a direct effect on a key virulence factor of Candida albicans, its secreted aspartyl proteinase (Sap). Although protease inhibitors can attenuate Candida adhesion to human epithelial cells, their effects on adhesion to acrylic substances, which is a common component of oral appliances, is unknown. This study investigated whether protease inhibitors affect C. albicans adhesion to acrylic substances. C. albicans suspensions were pretreated with different concentrations of saquinavir, ritonavir or indinavir for 1 h and allowed to adhere on acrylic strips, which had been pretreated with pooled human saliva for 30 min, for another hour in the presence of each drug. The test groups showed a significantly lower degree of adhesion than the controls. Adhesion was reduced by 50% at drug concentrations of 100, 100 and 20 μmol l(-1) for saquinavir, ritonavir and indinavir respectively. In conclusion, protease inhibitors attenuated C. albicans adhesion to an acrylic surface in vitro in a dose-dependent manner, and different protease inhibitors exhibited different degrees of inhibition.
© 2009 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19538521     DOI: 10.1111/j.1439-0507.2009.01743.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  8 in total

1.  Do Candida spp. "read" Nietzsche? Can xenobiotics modulate their aggressiveness? Proposition that chemicals may interfere in their virulence attributes.

Authors:  Edvaldo Antonio Ribeiro Rosa
Journal:  Mycopathologia       Date:  2011-10-11       Impact factor: 2.574

2.  Protease expression by microorganisms and its relevance to crucial physiological/pathological events.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2011-03-26

3.  HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2010-02-26

4.  Current and promising pharmacotherapeutic options for candidiasis.

Authors:  Liliana Scorzoni; Beth Burgwyn Fuchs; Juliana Campos Junqueira; Eleftherios Mylonakis
Journal:  Expert Opin Pharmacother       Date:  2021-02-04       Impact factor: 3.889

Review 5.  Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.

Authors:  L O Santos; A S Garcia-Gomes; M Catanho; C L Sodre; A L S Santos; M H Branquinha; C M d'Avila-Levy
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

6.  Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans-In Silico, In Vitro and In Vivo Approaches.

Authors:  André L S Santos; Lys A Braga-Silva; Diego S Gonçalves; Lívia S Ramos; Simone S C Oliveira; Lucieri O P Souza; Vanessa S Oliveira; Roberto D Lins; Marcia R Pinto; Julian E Muñoz; Carlos P Taborda; Marta H Branquinha
Journal:  J Fungi (Basel)       Date:  2021-05-28

7.  The effects of secreted aspartyl proteinase inhibitor ritonavir on azoles-resistant strains of Candida albicans as well as regulatory role of SAP2 and ERG11.

Authors:  Wenli Feng; Jing Yang; Yan Ma; Zhiqin Xi; Xiaoqin Zhao; Xiaoxia Zhao; Min Zhao
Journal:  Immun Inflamm Dis       Date:  2021-05-05

8.  Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro.

Authors:  Raimunda Sâmia Nogueira Brilhante; Érica Pacheco Caetano; Giovanna Barbosa Riello; Glaucia Morgana de Melo Guedes; Débora de Souza Collares Maia Castelo-Branco; Maria Auxiliadora Bezerra Fechine; Jonathas Sales de Oliveira; Zoilo Pires de Camargo; Jacó Ricarte Lima de Mesquita; André Jalles Monteiro; Rossana de Aguiar Cordeiro; Marcos Fábio Gadelha Rocha; José Júlio Costa Sidrim
Journal:  Braz J Infect Dis       Date:  2015-12-31       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.